Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Anti-COVID-19 Sulfonamides: A DFT, Docking and ADMET Study

Author(s): Ashique Al Hoque, Chayan Guha, Nayim Sepay, Sankar P. Dey and Umesh C. Halder*

Volume 3, Issue 1, 2022

Published on: 01 December, 2021

Article ID: e221221194872 Pages: 8

DOI: 10.2174/2666796702666210719103409

Price: $65

Abstract

Background: The development of a specific curative drug or prophylactic and vaccine is urgently required to cure COVID-19. Sulfonamide and its derivatives are famous for their multifaceted antibiotic and antiviral activities against verities of a pathogen.

Objective: The objective of this study is to find new potential molecules for COVID-19 treatment. We tested some sulfonamide molecules (including antiviral compounds) as SARS CoV-2 Mpro inhibitors.

Methods: In this study, the Density Functional Theory (DFT) and Docking study have been utilized for protein-small molecule affinity prediction. The SwissADME server was used for pharmacokinetics and drug-like likeness prediction, and the Pred-hERG server was employed for cardiotoxicity prediction.

Results: In this study, sixteen sulfonamides have been investigated in silico, with a perspective to obtaining a potential anti-covid compound. The sulfonamides have been subjected to molecular docking with SARS CoV-2 Mpro, mainly responsible for viral infection and replication. We discover the molecular flexibility and charge distribution profoundly affecting the binding of the compounds to the protein. Moderately flexible (six rotatable bond) and less polar (sufficient hydrophobic) sulfonamide are favorable for strong binding with the enzyme. Here, the bioavailability properties like adsorption, distribution, metabolism, excretion, pharmacokinetics, and potential toxicity of these compounds have also been checked.

Conclusion: Low cardio-toxicity and high bioavailability make these sulfonamides a good anti- COVID-19 drug option. The sulfonamide 16 was found to be the best.

Keywords: Sulfonamides, COVID-19, SARS CoV-2 Mpro, molecular docking, ADME, cardio-toxicity.

Graphical Abstract

[1]
Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[2]
Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg 2020; 78: 185-93.
[http://dx.doi.org/10.1016/j.ijsu.2020.04.018] [PMID: 32305533]
[3]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[4]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[5]
Ye T, Zhong Z, García-Sastre A, Schotsaert M, De Geest BG. Current status of covid-19 (pre)clinical vaccine development. Angew Chem Int Ed Engl 2020; 59(43): 18885-97.
[http://dx.doi.org/10.1002/anie.202008319] [PMID: 32663348]
[6]
Ramajayam R, Tan K-P, Liang P-H. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem Soc Trans 2011; 39(5): 1371-5.
[http://dx.doi.org/10.1042/BST0391371] [PMID: 21936817]
[7]
Ren Z, Yan L, Zhang N, et al. The newly emerged SARS-like coronavirus HCoV-EMC also has an “Achilles’ heel”: Current effective inhibitor targeting a 3C-like protease. Protein Cell 2013; 4(4): 248-50.
[http://dx.doi.org/10.1007/s13238-013-2841-3] [PMID: 23549610]
[8]
Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020; 582(7811): 289-93.
[http://dx.doi.org/10.1038/s41586-020-2223-y] [PMID: 32272481]
[9]
Graham JS, Patrick L. An introduction to medicinal chemistry. Available from: https://global.oup.com/academic/product/an-introduction-to-medicinal-chemistry-9780198749691?cc=jp&lang=en&
[10]
Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Anticancer and antiviral sulfonamides. Curr Med Chem 2003; 10(11): 925-53.
[http://dx.doi.org/10.2174/0929867033457647] [PMID: 12678681]
[11]
Reddy GSKK, Ali A, Nalam MNL, et al. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2′ ligands in pseudosymmetric dipeptide isosteres. J Med Chem 2007; 50(18): 4316-28.
[http://dx.doi.org/10.1021/jm070284z] [PMID: 17696512]
[12]
Gatell JM. From amprenavir to GW433908. J HIV Ther 2001; 6(4): 95-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11740410
[PMID: 11740410]
[13]
Sepay N, Sepay N, Al Hoque A, Mondal R, Halder UC, Muddassir M. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme. Struct Chem 2020; 31: 1-10.
[http://dx.doi.org/10.1007/s11224-020-01537-5] [PMID: 32412544]
[14]
Sepay N, Sekar A, Halder UC, Alarifi A, Afzal M. Anti- COVID-19 terpenoid from marine sources: A docking, admet and molecular dynamics study. J Mol Struct 2020; 1228: 129433.
[http://dx.doi.org/10.1016/j.molstruc.2020.129433] [PMID: 33071352]
[15]
Maddison JE, Watson ADJ, Elliott J. Antibacterial drugs.Small Anim Clin Pharmacol. Elsevier 2008; pp. 148-85.
[http://dx.doi.org/10.1016/B978-070202858-8.50010-5]
[16]
Kaysser L. Built to bind: Biosynthetic strategies for the formation of small-molecule protease inhibitors. Nat Prod Rep 2019; 36(12): 1654-86.
[http://dx.doi.org/10.1039/C8NP00095F] [PMID: 30976762]
[17]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7: 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[18]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(14-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[19]
Delaney JS. ESOL: estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci 2004; 44(3): 1000-5.
[http://dx.doi.org/10.1021/ci034243x] [PMID: 15154768]
[20]
Ali J, Camilleri P, Brown MB, Hutt AJ, Kirton SB. In silico prediction of aqueous solubility using simple QSPR models: the importance of phenol and phenol-like moieties. J Chem Inf Model 2012; 52(11): 2950-7.
[http://dx.doi.org/10.1021/ci300447c] [PMID: 23121381]
[21]
Fung M, Thornton A, Mybeck K, Wu JH-H, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Ther Innov Regul Sci 2001; 35(1): 293-317.
[http://dx.doi.org/10.1177/009286150103500134]
[22]
Gaussuian. Gaussian 09, Revision D.01. In: Wallingford, CT: Gaussian, Inc. 2009.
[23]
Gaussian. GaussView, Version 5.Wallingford, CT: Gaussian, Inc 2009.
[24]
Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: Current status and future challenges. Proteins 2006; 65(1): 15-26.
[http://dx.doi.org/10.1002/prot.21082] [PMID: 16862531]
[25]
Braga RC, Alves VM, Silva MFB, et al. Pred-hERG: A novel web-accessible computational tool for predicting cardiac toxicity. Mol Inform 2015; 34(10): 698-701.
[http://dx.doi.org/10.1002/minf.201500040] [PMID: 27490970]

Rights & Permissions Print Cite
Article Metrics
13
2
© 2024 Bentham Science Publishers | Privacy Policy